Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 18Neoplasm Metastasis 10Triple Negative Breast Neoplasms 9Lung Neoplasms 9Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Endometrial Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Vulvar Neoplasms 1Vomiting 1Uterine Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cystic Neoplasm 1Pancreatic Adenocarcinoma Metastatic 1

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1HMPL-013 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gastric Cancer Adenocarcinoma Metastatic × Taxes × Clear all
NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡